Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Daniel Ran, Chief Financial Officer of Nano-X Imaging Ltd. (NASDAQ:NNOX), acquired 1,000 shares of the company’s ordinary shares on September 5, 2025. The purchase, made near the stock’s 52-week low of $3.63, came as technical indicators from InvestingPro suggest the stock is in oversold territory. The shares were purchased at $3.65, totaling $3,650.
Following the transaction, Ran directly owns 6,950 ordinary shares of Nano-X Imaging Ltd. The company maintains a strong liquidity position with a current ratio of 4.19, and according to InvestingPro analysis, holds more cash than debt on its balance sheet. Get access to 8 more exclusive ProTips and comprehensive valuation metrics with an InvestingPro subscription.
In other recent news, Nano-X Imaging announced that its HealthOST software has received MDR CE Mark clearance, indicating compliance with European health, safety, and environmental protection standards. HealthOST is an AI-powered tool designed to assess vertebral height loss and bone mineral density through routine CT scans, which are indicators of musculoskeletal conditions like osteoporosis. This development negates the need for additional imaging procedures or extra time from patients. Additionally, Cantor Fitzgerald has reaffirmed its Overweight rating on Nano-X Imaging, maintaining a price target of $8.00. This rating reflects the firm’s continued confidence in the company’s prospects following the HealthOST software announcement. These recent developments highlight Nano-X Imaging’s ongoing advancements in medical imaging technology.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.